Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.22 USD

29.22
24,234,574

-0.05 (-0.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $29.21 -0.01 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Pfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study

Pfizer's (PFE) breast cancer candidate demonstrates superiority over chemotherapy in phase III study in previously treated breast cancer patients.

    4 Drug/Biotech Stocks That Could Be Buyout Targets in 2018

    Biotech mergers and acquisitions, which were quite lean in 2017, may pick up significantly in 2018 if the proposed tax reforms are finally approved.

      Pfizer Reports Updated Data from Phase III Study on Ibrance

      Pfizer (PFE) releases impressive new data of a post-hoc analysis from a phase III study on the combo therapy of Ibrance and Femara for the first-line treatment of ER+, HER2- metastatic breast cancer.

        Can Drug/Biotech M&A Rebound Next Year After Bleak 2017?

        Quite a few pharmaceutical industry mergers may be in the cards in 2018 if the proposed tax reforms are finally approved.

          Arpita Dutt headshot

          5 Top-Ranked Drug Stocks that are Broker Favorites

          With the pharma and biotech sector bouncing back in 2017, here is a look at five drug stocks including Sarepta (SRPT) that are broker favorites.

            Pfizer Wins China & Asia-Pacific Rights to Anti-Fungal Drug

            Pfizer (PFE) inks a deal to buy exclusive rights to develop and commercialize Basilea Pharmaceutica's anti-fungal treatment, Cresemba, in the Asia-Pacific region and China.

              3 Drug/Biotech Stocks in Focus on World AIDS Day

              On World AIDS Day, we look into some of the key pharma companies in the HIV market that are developing drugs to address the life threatening disease.

                Arpita Dutt headshot

                Gilead & 3 Other Drug Stocks in Focus this World AIDS Day

                With 36.7 million people living with HIV, there remains significant need for new and improved drugs in this corner of the market that has players like Gilead (GILD).

                  Glaxo Begins Phase III Study on Injection to Prevent HIV

                  Glaxo (GSK) announces start of a large late-stage African study on an experimental long-acting injection for the prevention of HIV.

                    Arpita Dutt headshot

                    Pharma Stock Roundup: Pfizer/Merck KGaA Drug Fails in Study, Teva CEO Announces Changes

                    Key highlights this week include changes announced by Teva's CEO and Pfizer (PFE)/Merck KGaA's data presentation. Reports about Amazon's plans to enter the drug market also made headlines.

                      Glaxo Stock Down So Far This Year: Is a Reversal in Store?

                      Glaxo's shares have declined 7.9% this year so far.

                        Pfizer/Merck KGaA's Bavencio Fails in Gastric Cancer Study

                        Pfizer & Merck KGaA's (MKGAF) Bavencio/avelumab fails in a phase III study evaluating it for the treatment of gastric cancer in the third-line setting.

                          Glaxo, Pfizer's ViiV Healthcare Begins HIV Drug Combo Study

                          Glaxo (GSK) and partner Pfizer's ViiV Healthcare commences a phase III study on combo regimen of cabotegravir and rilpivirine for treatment of adults with virally suppressed HIV-1 infection.

                            2 Large-Cap Drug Stocks Missing Out on Industry Rally in '17

                            Most drug companies with a larger market cap have seen their share price rising this year. However, a couple of large-cap pharma companies have witnessed a downside this year.

                              3 Companies Competing to Gain Lead in Ovarian Cancer Market

                              Three companies including a major pharma player are developing drugs for the treatment of ovarian cancer using a new technology instead of chemotherapy and competing to gain market share.

                                Stock Market News For Nov 22, 2017

                                Benchmarks finished in the green on Tuesday following gains in the technology and healthcare sectors

                                  J&J & Glaxo Get FDA Approval for First Two-Drug HIV Regimen

                                  J&J (JNJ) and Glaxo received FDA approval for Juluca, a two-drug complete regimen of Tivicay/rilpivirine and Edurant/dolutegravir as a single tablet for the treatment of HIV-1 infection.

                                    Amgen (AMGN) Unveils Auto Injector Device for Enbrel in US

                                    Amgen launched its Enbrel Mini with AutoTouch, a new auto injector device for Enbrel in the United States.

                                      Pfizer's Cancer Drug Sutent Gets FDA Nod for Label Expansion

                                      Pfizer (PFE) secures an FDA approval for Sutent's label expansion as an adjuvant treatment of recurrent renal cell carcinoma.

                                        Cancer Space Update: Label Expansion for Three Major Drugs

                                        This week three major drugs received approval for label expansion in new indications. Moreover, a small biotech launched its first drug as a treatment for kidney cancer.

                                          AstraZeneca's Faslodex Gets FDA Nod for Use With Verzenio

                                          AstraZeneca's (AZN) drug Faslodex received FDA approval for a new indication.

                                            Arpita Dutt headshot

                                            Novo Nordisk & 4 Other Pharma Stocks in Focus on World Diabetes Day

                                            Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.

                                              Merck (MRK) Gets CHMP Nod for Infection Candidate Prevymis

                                              CHMP has given a positive opinion recommending the marketing approval of Merck's (MRK) Prevymis for the prevention of CMV infection.

                                                The Zacks Analyst Blog Highlights: Pfizer, Occidental Petroleum, Charles Schwab, Prudential and S&P Global

                                                The Zacks Analyst Blog Highlights: Pfizer, Occidental Petroleum, Charles Schwab, Prudential and S&P Global

                                                  Arena (ARNA) Completes Enrolment in Etrasimod Phase II Study

                                                  Arena (ARNA) completed full enrollment with 157 patients in a phase II study evaluating etrasimod in ulcerative colitis (UC). Results from the study are expected in the first quarter of 2018.